共 40 条
[1]
Pawlotsky JM(2014)New hepatitis C therapies; the toolbox, strategies, and challenges Gastroenterology 146 1176-1192
[2]
Lawitz E(2014)Simeprevir plus sofosbuvir with/without ribavirin for treating chronic HCV genotype 1 infection in prior null responders to peginterferon/ribavirin and treatment naïve patients (COSMOS) Lancet 384 1756-1765
[3]
Sulkowski MS(2015)Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant Hepatology 74 951-961
[4]
Ghalib R(2014)Hepatitis C in HIV-infected patients: impact of direct-acting antivirals Drugs 41 1153-1193
[5]
Rodriguez-Torres M(2002)Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence Clin Pharmacokinet 31 742-747
[6]
Younossi ZM(2003)Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro Drug Metab Dispos 54 A372-1055
[7]
Corregidor A(2011)Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone PK and PD [Abstract] Hepatology 56 A1353-770
[8]
Pungpapong S(2011)The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone [Abstract] Hepatology 62 1047-undefined
[9]
Aqel B(2015)Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4 J Hepatol 148 762-undefined
[10]
Leise M(2015)The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis Gastroenterology undefined undefined-undefined